World Allergy Organization Journal最新文献

{"title":"Comment on “Evaluating vaccination dosing strategies for SARS-CoV-2 in patients at high-risk for allergic reactions: Insights from vaccination campaign”","authors":"Hinpetch Daungsupawong PhD , Viroj Wiwanitkit MD","doi":"10.1016/j.waojou.2025.101121","DOIUrl":"10.1016/j.waojou.2025.101121","url":null,"abstract":"","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 10","pages":"Article 101121"},"PeriodicalIF":4.3,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145121151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A World Allergy Organization (WAO) manifesto for the worldwide approval of biologic therapies for food allergy","authors":"Alessandro Fiocchi MD , Bryan Martin DO , Gary Wing-Kin Wong MD , Motohiro Ebisawa MD, PhD , Lucia Lo Scalzo , Francesca Galletta MD , Stefania Arasi MD, MSc, PhD , Ignacio J. Ansotegui MD, PhD , Maryam Ali Al-Nesf Al-Mansouri MD , Sandra N. Gónzalez Díaz MD, PhD , Jonathan A. Bernstein MD , Elham Hossny MD, PhD , Hiroshi Chantaphakul MD , Luciana K. Tanno MD, PhD , Tinatin Chikovani MD, PhD , David M. Lang MD , Luz Fonacier MD , Hideaki Morita MD , Mary Beth Fasano MD, MSPH , José Antonio Ortega-Martell MD , Mário Morais Almeida MD","doi":"10.1016/j.waojou.2025.101113","DOIUrl":"10.1016/j.waojou.2025.101113","url":null,"abstract":"","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 10","pages":"Article 101113"},"PeriodicalIF":4.3,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145097980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of a major house dust mite allergen Der p 22 among Malaysian adult population","authors":"Kavita Reginald PhD ,&nbsp;Smyrna Moti Rawanan Shah MSc ,&nbsp;Amanda Sandra Lestari Lee BSc ,&nbsp;Yang Yie Sio PhD ,&nbsp;Fook Tim Chew PhD","doi":"10.1016/j.waojou.2025.101117","DOIUrl":"10.1016/j.waojou.2025.101117","url":null,"abstract":"<div><h3>Background</h3><div>House dust mites (HDM) are a major trigger factor of allergic diseases worldwide.</div></div><div><h3>Objective</h3><div>To characterize the group 22 allergen from the HDM <em>Dermatophagoides pteronyssinus</em> among Malaysian atopic adults.</div></div><div><h3>Methods</h3><div>Recombinant Der p 22 and 33 alanine mutants were expressed in <em>Escherichia coli</em> and purified. Specific IgE levels to group 22 allergens were measured in serum samples from a combined cohort of Malaysian adults (n = 176) and participants from the SMCGES sub-cohort (n = 755), with responses classified by ImmunoCAP classes. Age- and gender-adjusted multivariate logistic regression was used to assess associations between Class 3+ group 22-specific IgE responses (&gt;3.5 IU/mL) and clinical diagnoses of asthma, allergic rhinitis (AR), and atopic dermatitis (AD). IgE inhibition assays were performed to evaluate the presence of unique epitopes in Der p 22 relative to its homologue Der p 2. Epitope mapping was performed using 33 single-alanine substitution mutants of Der p 22. Statistical analyses were carried out using GraphPad Prism and logistic regression models.</div></div><div><h3>Results</h3><div>Recombinant Der p 22 was expressed and purified as a 17.2 kDa protein. Among 149 atopic Malaysian adults, 54% had detectable sIgE to Der p 22. IgE inhibition assays demonstrated partial cross-reactivity between Der p 22 and Der p 2. High-level group 22-specific IgE responses (Class 3+) were associated with an increased risk of asthma (OR = 1.73, 95% CI = 0.98–3.00, p = 0.0524) and significantly associated with the presence of atopic comorbidities including AR and AD (all p &lt; 0.05). Epitope mapping identified to 6 critical residues, K10, H35, R43, D106, R117 and R130, where alanine substitution led to a marked reduction in IgE binding (median reduction &gt;95%).</div></div><div><h3>Conclusion</h3><div>Der p 22 is a clinically relevant HDM allergen in the Malaysian adult population. It harbours both unique and shared IgE epitopes with Der p 2, highlighting its value for inclusion in molecular diagnostic panels to improve allergen sensitization profiling. Alanine mutation to 6 amino acid residues of Der p 22 significantly reduced IgE binding, suggesting its potential as a candidate hypoallergen molecule in allergen-specific immunotherapy.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 10","pages":"Article 101117"},"PeriodicalIF":4.3,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145098033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Managing in-flight allergic emergencies: Challenges and solutions","authors":"Rita Aguiar MD,&nbsp;Raquel Baptista-Pestana MD,&nbsp;Mário Morais-Almeida MD","doi":"10.1016/j.waojou.2025.101114","DOIUrl":"10.1016/j.waojou.2025.101114","url":null,"abstract":"","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 10","pages":"Article 101114"},"PeriodicalIF":4.3,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145050574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between circulating thyroperoxidase (TPO), anti-TPO IgE, anti-TPO IgG, and different clinical outcomes in chronic urticaria: A hypothesis-generating study","authors":"Juan-Felipe Lopez MD, MSc, PhD(c) ,&nbsp;Valentina Bedoya MSc ,&nbsp;Julián-Camilo Arango MSc, PhD ,&nbsp;Tonny-Williams Naranjo MSc, PhD ,&nbsp;Elizabeth Garcia MD, EAC ,&nbsp;Jorge Sanchez MD, EAC, MSc, PhD","doi":"10.1016/j.waojou.2025.101116","DOIUrl":"10.1016/j.waojou.2025.101116","url":null,"abstract":"<div><h3>Background</h3><div>In chronic spontaneous urticaria (CSU), multiple biomarkers have been described, including autoantibodies against thyroperoxidase (TPO). However, the simultaneous analysis of both IgE anti-TPO and IgG anti-TPO alongside blood TPO has not been performed.</div></div><div><h3>Objective</h3><div>We conducted this hypothesis-generating study to evaluate the association between blood TPO, anti-TPO IgE, and anti-TPO IgG and explore their relationships with some clinical variables.</div></div><div><h3>Methods</h3><div>Patients aged 12–80 years with a clinical diagnosis of CSU were included in this study. First, the biomarkers between a CSU group and a non-CSU group were compared (case–control design). Second, the relationship between the biomarkers and clinical characteristics was explored in the CSU group with a twelve-month follow-up.</div></div><div><h3>Results</h3><div>The blood concentration of TPO was higher in the CSU group than in the control group, though this was not statistically significant (median 3.8 ng/mL vs. 13.3 ng/mL <em>p</em> = 0.4). The blood concentration of TPO was not associated with the presence of anti-TPO IgE or IgG. A total of 42 patients (61.2% versus 9.3% in non-CSU group) had anti-TPO IgG (29.4%) or anti-TPO IgE (42.6%) autoantibodies, and 7 patients (10.2%) had both. In the exploratory analysis, anti-TPO IgE and anti-TPO IgG were associated with different clinical clusters.</div></div><div><h3>Conclusion</h3><div>In this hypothesis-generating study, TPO levels do not appear to determine the presence of autoantibodies in patients with CSU. About half of patients with CSU have either an IgE or IgG autoantibody against TPO, but few patients have both, and each autoantibody is associated with a different clinical profile, suggesting that there are perhaps independent CSU mechanisms with a common target. Future studies are required to confirm this hypothesis.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 10","pages":"Article 101116"},"PeriodicalIF":4.3,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145050575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improvement of the therapeutic management of allergic patients in Europe – An expert think tank's position paper on allergen immunotherapy","authors":"Oliver Pfaar MD ,&nbsp;Maria Beatrice Bilò MD ,&nbsp;Péter Csonka MD ,&nbsp;Frédéric de Blay MD ,&nbsp;Monika Gappa MD ,&nbsp;Radoslaw Gawlik MD ,&nbsp;Philippe Gevaert MD ,&nbsp;Susanne Halken MD ,&nbsp;Valerie Hox MD ,&nbsp;Jasper Kappen MD ,&nbsp;Irena Krčmová MD ,&nbsp;Guillaume Lezmi MD ,&nbsp;Eloína González-Mancebo MD ,&nbsp;Erik Melén MD ,&nbsp;Javier Domínguez-Ortega MD ,&nbsp;Francesca Puggioni MD ,&nbsp;Sverre Steinsvåg MD ,&nbsp;Margitta Worm MD ,&nbsp;Eike Wüstenberg MD","doi":"10.1016/j.waojou.2025.101109","DOIUrl":"10.1016/j.waojou.2025.101109","url":null,"abstract":"<div><div>Respiratory allergies are a major global health issue due to their high prevalence and burden on patients, societies, and the health care system. In addition to symptom-relieving pharmacotherapy, allergen immunotherapy (AIT) is the only disease-modifying treatment option currently available that has the potential to prevent disease progression and the onset of asthma. The importance of AIT varies greatly from country to country. To discuss the different aspects of AIT, 20 experts from 12 European countries met for the First European Think Tank on Allergen Immunotherapy. The aim of the meeting was to formulate an expert position for improving the clinical care of patients with respiratory allergies in Europe, particularly concerning the use of AIT. The lacking class effect requires a product-specific assessment of AIT products for the most common allergens available in different European countries. Adherence, appropriate prescription, and early initiation — potentially to prevent disease progression — were identified as most important challenges for practical use of AIT. The shared decision-making on either sublingual or subcutaneous AIT may be based on safety and efficacy profiles, patient preferences, and clinical setting. Future challenges with regard to the application of AIT are as follows: to increase awareness for AIT among payers, health care providers, pharmacists, and patients; to better define patients who benefit the most of AIT; to improve the training of general practitioners on AIT as the first point of contact for allergy patients regarding allergy diagnosis and treatment, including AIT; to increase the awareness of AIT as a causal treatment option; to improve the training of primary care pediatricians with regard to AIT to ensure early initiation of AIT in cooperation with allergy specialists; to enhance the guidance of physicians through relevant AIT guidelines; and to provide them with more detailed scientific guidance for selecting the adequate products to achieve optimal benefits for their patients.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 10","pages":"Article 101109"},"PeriodicalIF":4.3,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145050576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world treatment patterns and burden-of-disease of sub-optimally controlled hereditary angioedema","authors":"Henriette Farkas MD, PhD ,&nbsp;Emel Aygören-Pürsün MD ,&nbsp;Didier G. Ebo MD, PhD ,&nbsp;Noemi Bara MD ,&nbsp;Fotis Psarros MD ,&nbsp;Francois Gavini MSc ,&nbsp;Nawal Bent-Ennakhil MSc ,&nbsp;Laura Sayegh MScA ,&nbsp;Irmgard Andresen MD","doi":"10.1016/j.waojou.2025.101100","DOIUrl":"10.1016/j.waojou.2025.101100","url":null,"abstract":"<div><h3>Background</h3><div>Hereditary angioedema (HAE) is a rare disease characterized by unpredictable, recurrent subcutaneous or submucosal swelling that negatively impacts patients’ health-related quality of life (HRQoL). Despite treatment goals aimed at achieving complete control of the disease and normalizing patients' lives, the disease remains poorly controlled for some patients.</div></div><div><h3>Objectives</h3><div>To describe the demographic, clinical and treatment characteristics, as well as the HRQoL impairment of patients with sub-optimally controlled HAE type I/II per treating physician's judgment, focusing on understanding the factors influencing the burden of illness.</div></div><div><h3>Methods</h3><div>A chart review was conducted at 32 HAE care centers across 18 European countries, Canada, and Israel between April 2022 and January 2023 in 214 patients aged ≥12 years with HAE type I/II sub-optimally controlled with on-demand treatment (ODT) and/or long-term prophylaxis (LTP). Patients receiving lanadelumab were excluded, as it was not yet widely available during the eligibility period. A cross-sectional survey at patient enrollment included the Angioedema Quality of Life (AE-QoL) and EQ-5D-5L questionnaires to assess the impact of HAE on HRQoL.</div></div><div><h3>Results</h3><div>Patients with uncontrolled HAE had a mean (standard deviation [SD]) of 9.9 (13) attacks per year, with a mean (SD) duration of 1.9 (1) days per attack. During the one-year observation period, 50.5% of patients were on ODT only, 36.0% used LTP and ODT concurrently, 6.5% used LTP without ODT, and 7.0% were untreated. Attenuated androgens (AA; stanozolol and danazol) in LTP were used by 24.7% of patients, while tranexamic acid (TA) and C1-esterase inhibitor (C1–INH) replacement products were used for LTP by 9.8% and 6.5%, respectively. The mean (SD) AE-QoL total score was 44.4 (24.0), indicating a moderate level of impairment, with women experiencing worse HRQoL (total score of 50.9 [SD 24] vs 37.3 [SD 23] in men) [where the minimal clinically important difference is 6 points] [1]. HRQoL worsened with increasing attack rates, from 41.4 (SD 24.0) among patients with one to 5 attacks/year, still indicating moderate impairment in HRQoL, to 73.0 (SD 27.0) for patients with &gt;40 attacks/year.</div></div><div><h3>Conclusions</h3><div>Suboptimal disease control in HAE was associated with the use of ODT only, as well as LTP mainly with AA/TA. It imposes a substantial burden on patients’ HRQoL, more particularly, but not exclusively, for those with frequent attacks and for women. The results suggest a need for improved HAE management.</div><div><span><span>ClinicalTrial.gov</span><svg><path></path></svg></span> study identifier NCT04957641.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 9","pages":"Article 101100"},"PeriodicalIF":4.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144921726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparities in food allergy amongst British South Asian adult patients in central England","authors":"Toni Osborne MSc ,&nbsp;Gareth Walters PhD ,&nbsp;Richard Baretto PhD ,&nbsp;Mamidipudi Thirumala Krishna PhD","doi":"10.1016/j.waojou.2025.101099","DOIUrl":"10.1016/j.waojou.2025.101099","url":null,"abstract":"<div><h3>Background</h3><div>Published evidence suggests an increased burden of food allergy (FA) amongst ethnic minority groups resident the United States of America and Australia, with limited data from the United Kingdom. The West Midlands Regional Allergy Service serves British Caucasian White and Ethnic Minority Groups with a large proportion being British South Asian, making it important to explore ethnicity—based differences in clinical outcomes for FA.</div></div><div><h3>Aims</h3><div>To compare clinical outcomes of FA and other atopic diseases between Caucasian White and South Asian patients attending the regional allergy service in West Midlands.</div></div><div><h3>Methods</h3><div>This prospective cross-sectional, observational study (N = 29 White and N = 21 South Asian) used a structured questionnaire with dichotomous, multiple-choice, and scaled questions to gather data on age, ethnicity, FA (including allergens, allergic reactions, adrenaline auto-injector use, and emergency department visits), and other atopic conditions.</div></div><div><h3>Main results</h3><div>1.) South Asians had significantly (p = 0.006) more frequent FA reactions. 2.) Poorly controlled eczema and asthma were significantly (eczema p = 0.015, asthma p = 0.022) more common amongst South Asians. 3.) The burden of asthma, eczema, and allergic rhinitis was similar between groups. 4.) Significantly more White patients (p = 0.027) with asthma were on higher treatment steps.</div></div><div><h3>Conclusion</h3><div>British South Asian patients with FA attending the West Midlands regional allergy service had more frequent allergic reactions and poorly controlled asthma and eczema compared to British Caucasian White patients. This highlights the need for improved education and compliance. Larger multi-centre studies are needed to gain further insight into ethnicity-based disparities in FA.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 9","pages":"Article 101099"},"PeriodicalIF":4.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144997187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From cockpit to community: Time to stop the use of first-generation H1-antihistamines","authors":"Mário Morais-Almeida MD ,&nbsp;Raquel Baptista-Pestana MD ,&nbsp;Sandra N. González-Dĺaz MD, PhD ,&nbsp;Bryan L. Martin DO ,&nbsp;Gary W.K. Wong MD","doi":"10.1016/j.waojou.2025.101112","DOIUrl":"10.1016/j.waojou.2025.101112","url":null,"abstract":"","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 9","pages":"Article 101112"},"PeriodicalIF":4.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144997188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Wildfire and asthma - The prospective interventions","authors":"Xingxing Yuan PhD ,&nbsp;Liuxin Yang MD ,&nbsp;Chaofan Li MD ,&nbsp;Ousman Bajinka MSc, PhD ,&nbsp;Zhuying Li PhD","doi":"10.1016/j.waojou.2025.101110","DOIUrl":"10.1016/j.waojou.2025.101110","url":null,"abstract":"<div><div>The increasing global warming trend has led to a drier landscape, which has in turn resulted in an increased incidence of wildfires. The smoke emanating from these fires has consequences that extend beyond the loss of property. This comes with the wildfire season whose smoke emanations have implications beyond loss of property. Among the health concerns regarding wildfires and smoke are respiratory diseases, such as asthma. Asthma, as a heterogeneous disease, is directly linked to other types of smoke rather than cigarettes, traffic exhaust, and industrial chemicals. Wildfires have been shown to be associated with particulate matter that act as pollutants to human life. The unprecedented increase in emergency visits during wildfire seasons is of clinical significance for its association with asthma and other pulmonary disorders. Despite the efforts of wealthy communities or nations, which have faced episodes of wildfires in recent years, the most effective protocol is yet to be developed. Given the vulnerability of individuals, including asthmatics, to the smoke from wildfires, interventions should extend beyond emergency measures. This review aims to provide a comprehensive overview of the relationship between wildfires and asthma symptoms, exploring the underlying mechanisms both <em>in vitro</em> and <em>in vivo</em>. It also delves into the potential implications for science policies, communication strategies, research directions, and management strategies for asthma cases, emphasizing the importance of preventive measures. Furthermore, this review serves as a guideline for various sectors, offering a clear conceptual rationale for preventing and managing wildfire smoke-related asthma and other pulmonary diseases. The interventions are multi-sectoral and multidisciplinary concerns, and given the transboundary nature of smoke, it is imperative for all relevant parties to collaborate to minimize preventable deaths.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 9","pages":"Article 101110"},"PeriodicalIF":4.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144988005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}